FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1862563098> ?p ?o ?g. }

• W1862563098 endingPage "4.e17" @default.
• W1862563098 startingPage "4.e11" @default.
• W1862563098 abstract "Preclinical urothelial carcinoma models suggest activity of dasatinib, an oral SRC-family kinase (SFK) inhibitor. We sought to determine the feasibility and biologic activity of neoadjuvant dasatinib (Neo-D) in patients with muscle-invasive urothelial carcinoma of the bladder (miUCB) preceding radical cystectomy (RC).A prospective multisite phase II trial was conducted. Key eligibility criteria included: resectable miUCB (T2-T4a, N0, M0), and Eastern Cooperative Oncology Group performance status 0 to 1. Patients received oral Neo-D 100mg once daily for 28±7 days followed by RC 8 to 24 hours after the last dose. The primary end point was feasibility, defined as≥60% of patients with miUCB completing therapy without treatment-related dose-limiting toxicity (DLT). Pre- and posttreatment tumor immunohistochemistry of phosphorylated SFK (pSFK), Ki-67, and cleaved caspase (Cas)-3 results were analyzed by paired t test.The study completed full accrual with enrollment of 25 patients of whom 23 were evaluable for feasibility. The study achieved its primary end point with 15 patients (65%) completing therapy without treatment-related DLTs. DLTs included: fatigue (n = 2), pulmonary embolism, abdominal pain, supraventricular tachycardia, enteric fistula, hematuria, and dyspnea (n = 1 each). At RC, 5 patients (23%) had<pT2 disease. Analysis of pre- and posttreatment tumors demonstrated significantly decreased pSFK (P = 0.003) but no overall significant changes in Ki-67 or Cas3. In total, 4 cases demonstrated a nonsignificant decrease in Ki-67, of which 3 cases also demonstrated a decrease in pSFK and 2 cases had marginal increase in Cas3.Neo-D in miUCB patients was feasible and safe. Overall, significant inhibition of pSFK was observed without overall reduction of cellular proliferation or increase of apoptosis, although biologic anti-tumor activity may exist in a small subset of patients. These results highlight the potential utility of the neoadjuvant trial paradigm and suggest that clinical benefit of single-agent SFK inhibition in unselected patients with miUCB is unlikely." @default.
• W1862563098 created "2016-06-24" @default.
• W1862563098 creator A5001308517 @default.
• W1862563098 creator A5012620880 @default.
• W1862563098 creator A5013167180 @default.
• W1862563098 creator A5018275141 @default.
• W1862563098 creator A5018962359 @default.
• W1862563098 creator A5026593581 @default.
• W1862563098 creator A5027707597 @default.
• W1862563098 creator A5035913183 @default.
• W1862563098 creator A5036138286 @default.
• W1862563098 creator A5038143218 @default.
• W1862563098 creator A5042026897 @default.
• W1862563098 creator A5042631007 @default.
• W1862563098 creator A5044876102 @default.
• W1862563098 creator A5047940829 @default.
• W1862563098 creator A5048604566 @default.
• W1862563098 creator A5052069729 @default.
• W1862563098 creator A5060130342 @default.
• W1862563098 creator A5064974889 @default.
• W1862563098 creator A5065131405 @default.
• W1862563098 creator A5072698528 @default.
• W1862563098 creator A5078128168 @default.
• W1862563098 creator A5078996026 @default.
• W1862563098 creator A5081246052 @default.
• W1862563098 creator A5082300423 @default.
• W1862563098 date "2016-01-01" @default.
• W1862563098 modified "2023-10-16" @default.
• W1862563098 title "Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity" @default.
• W1862563098 cites W1968784805 @default.
• W1862563098 cites W1971208896 @default.
• W1862563098 cites W1975918912 @default.
• W1862563098 cites W1980789942 @default.
• W1862563098 cites W1990241283 @default.
• W1862563098 cites W1999937003 @default.
• W1862563098 cites W2002566754 @default.
• W1862563098 cites W2054399970 @default.
• W1862563098 cites W2068523052 @default.
• W1862563098 cites W2073175347 @default.
• W1862563098 cites W2084075250 @default.
• W1862563098 cites W2103561213 @default.
• W1862563098 cites W2113156769 @default.
• W1862563098 cites W2119507882 @default.
• W1862563098 cites W2120208667 @default.
• W1862563098 cites W2128042367 @default.
• W1862563098 cites W2143807312 @default.
• W1862563098 cites W2151278059 @default.
• W1862563098 cites W2155418737 @default.
• W1862563098 cites W2162720854 @default.
• W1862563098 cites W2166453367 @default.
• W1862563098 cites W2170552969 @default.
• W1862563098 cites W2325228859 @default.
• W1862563098 doi "https://doi.org/10.1016/j.urolonc.2015.08.005" @default.
• W1862563098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26362343" @default.
• W1862563098 hasPublicationYear "2016" @default.
• W1862563098 type Work @default.
• W1862563098 sameAs 1862563098 @default.
• W1862563098 citedByCount "13" @default.
• W1862563098 countsByYear W18625630982016 @default.
• W1862563098 countsByYear W18625630982017 @default.
• W1862563098 countsByYear W18625630982020 @default.
• W1862563098 countsByYear W18625630982022 @default.
• W1862563098 crossrefType "journal-article" @default.
• W1862563098 hasAuthorship W1862563098A5001308517 @default.
• W1862563098 hasAuthorship W1862563098A5012620880 @default.
• W1862563098 hasAuthorship W1862563098A5013167180 @default.
• W1862563098 hasAuthorship W1862563098A5018275141 @default.
• W1862563098 hasAuthorship W1862563098A5018962359 @default.
• W1862563098 hasAuthorship W1862563098A5026593581 @default.
• W1862563098 hasAuthorship W1862563098A5027707597 @default.
• W1862563098 hasAuthorship W1862563098A5035913183 @default.
• W1862563098 hasAuthorship W1862563098A5036138286 @default.
• W1862563098 hasAuthorship W1862563098A5038143218 @default.
• W1862563098 hasAuthorship W1862563098A5042026897 @default.
• W1862563098 hasAuthorship W1862563098A5042631007 @default.
• W1862563098 hasAuthorship W1862563098A5044876102 @default.
• W1862563098 hasAuthorship W1862563098A5047940829 @default.
• W1862563098 hasAuthorship W1862563098A5048604566 @default.
• W1862563098 hasAuthorship W1862563098A5052069729 @default.
• W1862563098 hasAuthorship W1862563098A5060130342 @default.
• W1862563098 hasAuthorship W1862563098A5064974889 @default.
• W1862563098 hasAuthorship W1862563098A5065131405 @default.
• W1862563098 hasAuthorship W1862563098A5072698528 @default.
• W1862563098 hasAuthorship W1862563098A5078128168 @default.
• W1862563098 hasAuthorship W1862563098A5078996026 @default.
• W1862563098 hasAuthorship W1862563098A5081246052 @default.
• W1862563098 hasAuthorship W1862563098A5082300423 @default.
• W1862563098 hasConcept C121608353 @default.
• W1862563098 hasConcept C126322002 @default.
• W1862563098 hasConcept C126894567 @default.
• W1862563098 hasConcept C141071460 @default.
• W1862563098 hasConcept C143998085 @default.
• W1862563098 hasConcept C170493617 @default.
• W1862563098 hasConcept C203092338 @default.
• W1862563098 hasConcept C2775910329 @default.
• W1862563098 hasConcept C2779536868 @default.
• W1862563098 hasConcept C2780352672 @default.
• W1862563098 hasConcept C42362537 @default.

• next